MA56512A - Recristallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans du méthyl tert-butyléther (mtbe) et moins de 5 % en poids d'un anti-solvant aliphatique - Google Patents

Recristallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans du méthyl tert-butyléther (mtbe) et moins de 5 % en poids d'un anti-solvant aliphatique

Info

Publication number
MA56512A
MA56512A MA056512A MA56512A MA56512A MA 56512 A MA56512 A MA 56512A MA 056512 A MA056512 A MA 056512A MA 56512 A MA56512 A MA 56512A MA 56512 A MA56512 A MA 56512A
Authority
MA
Morocco
Prior art keywords
dimethyltryptamine
dmt
meo
mtbe
recrystallization
Prior art date
Application number
MA056512A
Other languages
English (en)
Inventor
Leonard Gerard Francis Patrick
Shaun Neil Robinson
Theis Terwey
Original Assignee
Gh Res Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gh Res Ireland Limited filed Critical Gh Res Ireland Limited
Publication of MA56512A publication Critical patent/MA56512A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA056512A 2019-06-19 2020-06-19 Recristallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans du méthyl tert-butyléther (mtbe) et moins de 5 % en poids d'un anti-solvant aliphatique MA56512A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181211.4A EP3753923A1 (fr) 2019-06-19 2019-06-19 Récrystallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans de méthyl tert.-butyl éther (mtbe) sans ajouter un antisolvant

Publications (1)

Publication Number Publication Date
MA56512A true MA56512A (fr) 2022-04-27

Family

ID=66999576

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056512A MA56512A (fr) 2019-06-19 2020-06-19 Recristallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans du méthyl tert-butyléther (mtbe) et moins de 5 % en poids d'un anti-solvant aliphatique

Country Status (11)

Country Link
US (1) US20220324802A1 (fr)
EP (2) EP3753923A1 (fr)
JP (1) JP2022537208A (fr)
KR (1) KR20220062489A (fr)
CN (1) CN114423738A (fr)
AU (1) AU2020296286A1 (fr)
BR (1) BR112021025526A2 (fr)
CA (1) CA3144038A1 (fr)
IL (1) IL289085A (fr)
MA (1) MA56512A (fr)
WO (1) WO2020254584A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023186834A1 (fr) 2022-03-27 2023-10-05 GH Research Ireland Limited Sel de bromhydrate cristallin de 5-meo-dmt

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1693366A1 (fr) * 1998-12-11 2006-08-23 Virginia Commonwealth University Ligands selectifs du recepteur de 5-HT6
MX2021009941A (es) * 2019-02-22 2021-12-10 Gh Res Ireland Limited 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de la depresion.

Also Published As

Publication number Publication date
US20220324802A1 (en) 2022-10-13
KR20220062489A (ko) 2022-05-17
WO2020254584A1 (fr) 2020-12-24
AU2020296286A1 (en) 2022-01-27
EP3753923A1 (fr) 2020-12-23
BR112021025526A2 (pt) 2022-03-03
CN114423738A (zh) 2022-04-29
IL289085A (en) 2022-02-01
JP2022537208A (ja) 2022-08-24
EP3986864B1 (fr) 2024-03-13
EP3986864A1 (fr) 2022-04-27
CA3144038A1 (fr) 2020-12-24
EP3986864C0 (fr) 2024-03-13

Similar Documents

Publication Publication Date Title
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
MA56512A (fr) Recristallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans du méthyl tert-butyléther (mtbe) et moins de 5 % en poids d'un anti-solvant aliphatique
MX2022005232A (es) Degradadores de moleculas peque?as de helios y procedimientos de uso.
HRP20201157T1 (hr) Triciklički heterocikli za liječenje raka
PH12021551257A1 (en) Cyclic pantetheine derivatives and uses thereof
PH12017501060B1 (en) Pharmaceutical combination comprising a selective s1p1 receptor agonist
ZA202208051B (en) Protein degradation agent compound preparation method and application
MA54713A (fr) Forme posologique parentérale stable d'acétate de cétrorélix
MX2020003383A (es) Compuesto de griseofulvina y uso farmacéutico de este.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12020500461A1 (en) 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as il-17 and ifn-gamma inhibitors for treating autoimmune diseases and chronic inflammation
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
IL289786A (en) Cannabinoid history as pharmacologically active compounds and methods for their preparation
WO2011132901A3 (fr) Nouveaux dérivés de benzamide
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
EP3956316A4 (fr) Procédé de préparation de composés de strobilurine à activité fongicide et d'intermédiaires de ceux-ci
MX2022007044A (es) Compuesto y composicion como inhibidor de cinasa del receptor de los factores de crecimiento derivados de las plaquetas (pdgf).
TW200616614A (en) A pharmaceutical composition for treating spinocerebellar ataxia
PH12021551103A1 (en) 1,3,4-oxadiazolone compound and medicine
MX2022005440A (es) Polipeptido con efecto inhibidor de metaloproteasa de matriz 2 (mmp2).
WO2015010666A3 (fr) Dérivé de phénol et son utilisation
FR3084592B1 (fr) Composition cosmetique
HRP20220012T1 (hr) Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka
EP4058050A4 (fr) Système crispr/cas9 en tant qu'agent d'inhibition d'une infection par le polyome jc